NewAmsterdam Pharma (NAMS) Non-Current Assets (2021 - 2026)

NewAmsterdam Pharma has reported Non-Current Assets for 6 years, with the latest figure at $74.6 million in Q1 2026.

• Quarterly Non-Current Assets rose 6626.69% year-over-year to $74.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $267.5 million (up 5282.1% YoY) and the FY2025 annual result came in at $93.6 million, up 7653.44% from the prior year.
• Non-Current Assets slipped to $74.6 million in Q1 2026 per NAMS's latest filing, from $93.6 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $93.6 million in Q4 2025 and troughed at $306000.0 in Q4 2023.
• A 5-year average of $37.3 million and a median of $23.3 million in 2024 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2023: Non-Current Assets soared 8196447.84% in 2022, then tumbled 99.64% in 2023.
• Over 5 years, Non-Current Assets stood at $85.1 million in 2022, then sank by 99.64% to $306000.0 in 2023, then jumped by 294.44% to $1.2 million in 2024, then jumped by 7653.44% to $93.6 million in 2025, then slipped by 20.29% to $74.6 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $74.6 million, $93.6 million, and $54.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.